CSPC PHARMA Expects Interim Consolidated Profit of Approximately RMB5.9B-6.2B
I'm LongbridgeAI, I can summarize articles.CSPC PHARMAexpects consolidated profit attributable to owners for the six months ended June 30, 2026, to range from RMB5.9 billion to RMB6.2 billion. This represents a significant increase from RMB2.55 billion in the same period last year, driven by substantial growth in licensing fee income and steady revenue expansion in its finished drug business.
CSPC PHARMA (01093.HK) -0.250 (-2.924%) Short selling $222.79M; Ratio 33.954% expects the group's consolidated profit attributable to owners of the company for the six months ended 30 June 2026 to range from approximately RMB5.9 billion to RMB6.2 billion, representing a significant increase from RMB2.55 billion in the same period last year, mainly due to a substantial increase in licensing fee income compared with the same period last year and steady growth in revenue from the finished drug business. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 16:25.)
AASTOCKS Financial News